We are looking for moderators. If you would like to help moderate this board, please use the 'request to moderate board' link at top left and you will receive a confirmation that you have been added as a Co-Moderator. As a moderator you will have the ability to oversee discussions and make sure all posts are relevant.

You will also have the ability to add an advanced description for the stock. This is particularly useful if there are aspects of the company that you want to highlight and help others learn about the company's objectives. Photos and pictures are welcome. Don't be shy. Become an integral member of GEO's Culture

This stock is gaining momentum and if they are complaint the next quarters I guess they will attract new investors.

Friday, they had already higher than normal trading with a day range of 1.50-2.30.

In 2009 they earned $ 0,42 and the BV was $ 1,35. If you read the last press release they are promising better IR and corporate governance. If they promise what they are saying the of $ 1,50 is a bargain.

HARBIN, China, Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheet: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today that it has filed its annual report on Form 10-K for the fiscal year ended October 31, 2009 on time. In addition, the Company has filed all required quarterly and annual reports and is in compliance again with SEC filing requirements. Renhuang is committed to maintaining its current filer status and to providing investor transparency. The Company expects to report financial results for the first quarter ended January 31, 2010 on or before the filing deadline of March 17.

Renhuang filed its annual report on Form 10-K for the fiscal year ended October 31, 2009 on January 29, 2010. For the full fiscal year 2009, net sales were a record $43.4 million, as compared to $34.5 million for fiscal year 2008. Net income for 2009 was a record $14.8 million, or $0.41 per diluted share, as compared to net income of $10.3 million, or $0.29 per diluted share, for the same period in 2008.

"Regaining our ability to fulfill our filing requirements was an important milestone for Renhuang and demonstrated the Company's commitment to improving our corporate governance," said Mr. Shaoming Li, Renhuang's Chairman and CEO. "I am very proud of our record performance in fiscal 2009 while building momentum for fiscal 2010 and beyond. I look forward to updating the investment community on our growth progress, including plans to upgrade to a senior stock exchange."

Dutch,

Your english is better than mine, so don't worry.

I share your frustration.  I think many firms blame the IR if their stock goes down instead of the operations of the company. Then they fire the IR firm. So when operations improve they think IR won't help them. They are getting better though.

Maj, GeoTeam

A lot of Chinese companies have bad IR. Why they seek for a listing if they don't want that their stock price increases? A bad IR is in general a kill for a company, or at least for the stockprice.

What I am trying to say, a higher stock price benefits the stakeholders. So also current management. Why a lot of OTC and Pinksheet companies don't care about this?

An example: Sino Agri Food (SIAF). Great IR.........investor presentation etc. 

This is appreciated by investors.

PS. Sorry if my English is not always correct, my native language is Dutch, because I live in the Netherlands.  

Hello Dutch,

I do have RHGP on my radar. I interviewed them a few  years ago. Three things i need to consider:

1. Never had a good IR team

2. Missed guidance several times when i tracked them a few years ago

3. May require capital.

That being said, i think it may deserve to at least sell at book.

Maj, The GeoTeam

I was looking to Chinese Pharmaceuticals that are not yet fully discovered. Of course you have Lotus Pharmaceuticals (LTUS) that had a nice run up in price yesterday. What about Renhuang Pharmaceuticals (RHGP)?

I just looked at their last filing and saw H1 results were EPS $ 0,24.

Book Value PS $1,21

The only thing is in my opinion that IR is something they have to work on.

Who is familiar with this company and knows something more than the report filings?